CARDOZA GEORGE 4

What Happened
George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA (SOPH), was granted equity on April 2, 2026: 112,936 restricted stock units (RSUs) and 164,671 derivative awards (stock option-type award). Both grants are reported at an acquisition price of $0 (they are awards, not open-market purchases), for a combined total of 277,607 units. These are time-based grants that vest over multi-year schedules rather than immediately tradable shares.

Key Details

• Transaction date: April 2, 2026; Form filed April 3, 2026 (timely filing).
• Reported acquisition price: $0 for both awards (standard for grant reporting).
• Grant amounts: 112,936 RSUs (F1) and 164,671 derivative/option awards (F2); total 277,607 units.
• Vesting (RSUs, F1): 25% vests April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030.
• Vesting (options/derivative, F2): 25% vests April 2, 2027; remaining vests in equal monthly installments through April 2, 2030.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No 10b5-1 plan, tax withholding, sale, or late-filing flags noted in the filing excerpt.

Context
RSUs and option-style awards are common executive compensation designed to retain executives — they do not represent immediately tradable shares until vested (or exercised for options). Because these are grants (not purchases or sales), they are neutral in terms of immediate bullish/bearish signaling; they reflect compensation rather than an investment decision. The staged vesting means the awards will convert to exercisable/owned shares over the 2027–2030 period if the CFO remains employed.